Want to see HYPMY full AI Analyst Report?
HYPMY Stock Chart & Stats
$4.27
$0.08(2.01%)
At close: 4:00 PM EDT
$4.27
$0.08(2.01%)
Day’s Range― - ―
52-Week Range$3.86 - $5.19
Previous CloseN/A
Volume4.63K
Average Volume (3M)772.00
Market Cap
$3.11B
Enterprise Value$4.02K
Total Cash (Recent Filing)$1.58B
Total Debt (Recent Filing)$7.48B
Price to Earnings (P/E)8.5
Beta0.56
Next Earnings
Oct 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.87%
Share Statistics
EPS (TTM)2.68
Shares Outstanding704,009,030
10 Day Avg. Volume1,263
30 Day Avg. Volume772
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.86
P/FCF Ratio8.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable ProfitabilityHypera’s strong gross, EBIT, EBITDA, and net margins indicate meaningful brand, pricing, and operating-scale advantages in healthcare products. Sustained profitability provides resilience against cost pressure and supports reinvestment, debt reduction, and continued product development over the coming quarters.
Strong Cash GenerationRobust operating cash flow and free cash flow give Hypera internal funding capacity for product launches, plant investment, and balance-sheet repair. Cash generation that exceeds accounting profit also strengthens financial flexibility and reduces reliance on external financing over the medium term.
Product ExpansionRegulatory approval for semaglutide and the planned patented menopausal treatment expand Hypera’s addressable market beyond its established portfolio. These launches can add prescription growth and strengthen the product pipeline, while patent protection supports differentiation and commercial durability.
Bears Say
Remaining LeverageAlthough leverage is improving, net debt remains material relative to EBITDA and management still needs further deleveraging before considering broader capital allocation. This can constrain flexibility for acquisitions, buybacks, or higher distributions and leaves the company more exposed to financing costs.
Elevated Capital SpendingHigh near-term CapEx will absorb cash while plant expansions are completed, limiting the amount of free cash available for debt reduction and shareholder returns. The delayed reduction in investment intensity also extends the period before the benefits of a lower spending base can improve financial flexibility.
GLP-1 CompetitionHypera’s semaglutide opportunity is structurally attractive but exposed to intense competition from imports, compounding, and future entrants. These forces could pressure pricing, market share, and launch profitability, reducing the earnings contribution from the new product even after regulatory approval.
Hypera SA News
HYPMY FAQ
What was Hypera SA’s price range in the past 12 months?
Hypera SA lowest stock price was $3.86 and its highest was $5.19 in the past 12 months.
What is Hypera SA’s market cap?
Hypera SA’s market cap is $3.11B.
When is Hypera SA’s upcoming earnings report date?
Hypera SA’s upcoming earnings report date is Oct 27, 2026 which is in 46 days.
How were Hypera SA’s earnings last quarter?
Hypera SA released its earnings results on Aug 06, 2026. The company reported $0.138 earnings per share for the quarter.
Is Hypera SA overvalued?
According to Wall Street analysts Hypera SA’s price is currently Overvalued.
Does Hypera SA pay dividends?
Hypera SA pays a Quarterly dividend of $0.051 which represents an annual dividend yield of 5.87%. See more information on Hypera SA dividends here
What is Hypera SA’s EPS estimate?
Hypera SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hypera SA have?
Hypera SA has 704,009,030 shares outstanding.
What happened to Hypera SA’s price movement after its last earnings report?
Hypera SA reported an EPS of $0.138 in its last earnings report. Following the earnings report the stock price went up 0.908%.
Which hedge fund is a major shareholder of Hypera SA?
Currently, no hedge funds are holding shares in HYPMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hypera SA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.74%
12-Months-Change
Fundamentals
Return on Equity
5.87%
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hypera SA
Hypera S.A. is a prominent pharmaceutical enterprise primarily operating within Brazil. The company maintains a diverse product portfolio that includes a vast array of prescription medications, marketed under numerous brand names such as Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid. Beyond prescription drugs, Hypera S.A. also provides dermo-cosmetic solutions, notably through its Mantecorp Skincare line. Its consumer health segment features well-known brands including Apracur, Benegrip, Coristina d, Engov, Epocler, and Estomazil, among others. Furthermore, the company offers nutritional and vitamin supplements, with labels such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. Hypera S.A. is also a producer and distributor of a range of similar and generic medicines, including its Neo Química brand, as well as products identified by active ingredients like Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel. Initially known as Hypermarcas S.A., the company officially rebranded to Hypera S.A. in February 2018. Its corporate headquarters are located in São Paulo, Brazil.
HYPMY Company Deck
HYPMY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered a predominantly positive message: the company reported solid top-line growth (net revenue +8.5%, sell-out +7.6%), margin expansion (gross margin 61.8%), strong EBITDA (BRL 755m) and cash generation (operating cash flow BRL 819m, free cash flow BRL 638m), alongside strategic approvals and partnerships (Semavy ANVISA approval; patented menopausal treatment). Structural working capital improvements and a meaningful reduction in net debt support financial resilience. Near-term challenges include elevated marketing and CapEx, remaining leverage (2.1x LTM EBITDA), competition and informal channels in the GLP-1 market, and potential temporary inventory build for product launches. Overall, the positives — growth, margin expansion, robust cash flow, product approvals and strategic partnerships — materially outweigh the manageable near-term headwinds.View all HYPMY earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.02% Other Institutional Investors
99.96% Public Companies and
Individual Investors